Clinical Trials Logo

Acromegaly clinical trials

View clinical trials related to Acromegaly.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06372652 Not yet recruiting - Acromegaly Clinical Trials

A Phase 1 Study of TE-8214 Solution in Healthy Volunteers

Start date: May 2, 2024
Phase: Phase 1
Study type: Interventional

This is a Phase 1, first-in-human, randomized, double-blinded, placebo-controlled study to evaluate the safety, tolerability, and PK of TE-8214 in healthy volunteers. The study will assess single ascending doses (SAD) of TE-8214.

NCT ID: NCT06326853 Not yet recruiting - Acromegaly Clinical Trials

Neuroendocrine Mechanisms in Adiposity: An Integrated Approach to the Characterization of Potential Pharmacological Novel Targets Based on Experimental and Clinical Models

Start date: July 2024
Phase:
Study type: Observational

The goal of this observational study is to evaluate, retrospectively and prospectively, the effect of different hormonal and neuropeptide dysfunctions on the body composition of patients suffering from hypothalamic-pituitary pathologies, and to evaluate the potential beneficial effect of surgical and medical treatments with agonists and antagonists of hypothalamic neuropeptides, currently available, on the development and treatment of adiposity and negative cross-talk between adiposity and muscle/bone tissue

NCT ID: NCT05298891 Not yet recruiting - Acromegaly Clinical Trials

Hypoproteic Diet in Acromegaly

IpoProAcro
Start date: September 1, 2024
Phase: N/A
Study type: Interventional

Since protein and AAs are master regulator of GH and IGF-I secretion, we hypothesized that a low protein diet could reduce GH and IGF-I levels in acromegalic patients in addition to conventional therapy. Furthermore, we aim to explore metabolomic, microbiota, and micro-vesicle fingerprints of GH hypersecretion during conventional therapy and after a low protein diet

NCT ID: NCT04529356 Not yet recruiting - Headache Clinical Trials

The TMS Treatment for Postoperative Headache in GH Tumor

Start date: September 1, 2020
Phase: N/A
Study type: Interventional

Headache is a very common main complaint of patients with GH pituitary tumor, which has seriously affected the normal work and life of patients. Although the current surgery and drugs have a certain effect on patients with headache, the overall effect is not satisfied. However, the use of COX-2 inhibitors, non-steroidal anti-inflammatory drugs and other analgesics are only effective for some patients with headaches, and long-term use has adverse reactions. Therefore, it is necessary to seek new treatments for postoperative headaches in patients with GH pituitary tumors. Transcranial magnetic stimulation (TMS) modulates the excitability of the underlying cerebral cortex by applying a rapidly changing magnetic field on the surface of the scalp. It is a relatively simple and safe method. It is currently approved for treating depression, migraine, obsessive-compulsive disorder, and Alzheimer's disease. Several small clinical studies have proven that rTMS can be used to prevent and treat Headache. Therefore, this study aims to observe the efficacy and safety of TMS in the treatment of postoperative headache in patients with GH pituitary tumors.

NCT ID: NCT04066569 Not yet recruiting - Acromegaly Clinical Trials

Reproducibility and Utility of OGTT in Acromegaly

ACROTEST
Start date: September 10, 2019
Phase: N/A
Study type: Interventional

Prospective study of reproducibility and utility of growth hormone inhibition by oral glucose tolerance test for the diagnosis of acromegaly, in acromegalic and non-acromegalic subjects, with a randomized double-blind crossover over placebo arm in the group of acromegalic patients

NCT ID: NCT03439709 Not yet recruiting - Clinical trials for Acromegaly Due to Pituitary Adenoma

Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma

MERGE
Start date: March 1, 2018
Phase: Phase 3
Study type: Interventional

In this study, the investigators hypothesize that upfront gamma knife radiosurgery with drug therapy is superior in the treatment of growth hormone-secreting pituitary tumors after primary surgical treatment compared with the drug therapy alone. This study can provide useful clinical information in the treatment of patients with acromegaly.